Retatrutide Delivers 28.3% Weight Loss in Lilly's TRIUMPH-1 Phase 3 Trial

More like this

• Health09/23/2026@HealthDesk

  Lilly Submits Retatrutide to the FDA for Approval

  Eli Lilly·…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States

  Starts 03/31/2027ESTIMATED3 months late77% CONFIDENCEin 189 daysLilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.^[1]

  Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.

  0.81

  00
• Health09/20/2026@HealthDesk

  Maridebart Cafraglutide's Phase 3 Trial in Obesity Reads Out

  Amgen·…Thousand Oaks, United States

  Starts 12/26/2027ESTIMATED50% CONFIDENCEin 1.3 yearsClinicalTrials.gov^[1] lists 2027-12-26 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  Amgen's phase 3 trial of Maridebart Cafraglutide in obesity reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 3,200 participants. The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

  0.73

  00
• Health09/20/2026@HealthDesk

  Enicepatide's Phase 3 Trial in Obesity or Overweight Reads Out

  RocheBasel, Canton of Basel-Stadt, Switzerland

  Starts 07/24/2028ESTIMATED50% CONFIDENCEin 1.8 yearsClinicalTrials.gov^[1] lists 2028-07-24 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  Roche's phase 3 trial of Enicepatide in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.

  0.72

  00
• Health09/20/2026@HealthDesk

  Elecoglipron's Phase 3 Trial in Weight Management Reads Out

  AstraZeneca·…Cambridge, United Kingdom

  Starts 07/31/2028ESTIMATED50% CONFIDENCEin 1.9 yearsClinicalTrials.gov^[1] lists 2028-07-31 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  AstraZeneca's phase 3 trial of Elecoglipron in weight management reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,500 participants. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

  0.71

  00
• Health09/20/2026@HealthDesk

  Maridebart Cafraglutide's Phase 3 Trial in Heart Failure With Preserved Ejection Fraction Reads Out

  Amgen·…Thousand Oaks, United States

  Starts 06/30/2028ESTIMATED50% CONFIDENCEin 1.8 yearsClinicalTrials.gov^[1] lists 2028-06-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  Amgen's phase 3 trial of Maridebart Cafraglutide in heart failure with preserved ejection fraction reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,056 participants. This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.

  0.71

  00
• Health09/20/2026@TechDesk

  Lilly's Foundayo (Orforglipron) Weight-Loss Pill Approved by FDA

  Eli Lilly·…Indianapolis, Indiana

  Starts 04/01/2026CONFIRMED85% CONFIDENCE175 days agoLilly^[3] and the FDA^[4] approval letter date the approval April 1, 2026.

  The FDA approved Eli Lilly's Foundayo, a once-daily GLP-1 pill for weight loss that needs no food or water restrictions, with direct-to-consumer sales from April 6.

  0.71

  00
• Health09/20/2026@HealthDesk

  Camizestrant's Phase 3 Trial in Breast Cancer, Early Breast Cancer Reads Out

  AstraZeneca·…Cambridge, United Kingdom

  Starts 04/20/2027ESTIMATED50% CONFIDENCEin 209 daysClinicalTrials.gov^[1] lists 2027-04-20 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  AstraZeneca's phase 3 trial of Camizestrant in breast cancer, early breast cancer reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,300 participants. This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.

  0.70

  00
• Health09/20/2026@HealthDesk

  AZD6234's Phase 3 Trial in Obesity or Overweight Reads Out

  AstraZeneca·…Cambridge, United Kingdom

  Starts 08/11/2028ESTIMATED50% CONFIDENCEin 1.9 yearsClinicalTrials.gov^[1] lists 2028-08-11 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  AstraZeneca's phase 3 trial of AZD6234 in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,500 participants. The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

  0.70

  00
• Health09/20/2026@HealthDesk

  Maridebart Cafraglutide's Phase 3 Trial in Atherosclerotic Cardiovascular Disease Reads Out

  Amgen·…Thousand Oaks, United States

  Starts 06/30/2028ESTIMATED50% CONFIDENCEin 1.8 yearsClinicalTrials.gov^[1] lists 2028-06-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  Amgen's phase 3 trial of Maridebart Cafraglutide in atherosclerotic cardiovascular disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 12,800 participants. The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

  0.70

  00
• Health09/20/2026@HealthDesk

  Armour Thyroid's Phase 3 Trial in Hypothyroidism Reads Out

  AbbVie·…North Chicago, United States

  Starts 09/01/2027ESTIMATED50% CONFIDENCEin 343 daysClinicalTrials.gov^[1] gives the primary completion date only as 2027-09, an estimate by the sponsor, so the pin sits on the first of that month.

  AbbVie's phase 3 trial of Armour Thyroid in hypothyroidism reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,800 participants. This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone \[TSH\]) on synthetic T4 treatment. This study will also therefore evaluate the efficacy and safety of dose conversion from synthetic T4 therapy to Armour Thyroid therapy.

  0.68

  00
• Health09/20/2026@HealthDesk

  Elecoglipron's Phase 3 Trial in Type 2 Diabetes Mellitus Reads Out

  AstraZeneca·…Cambridge, United Kingdom

  Starts 07/05/2028ESTIMATED50% CONFIDENCEin 1.8 yearsClinicalTrials.gov^[1] lists 2028-07-05 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

  0.67

  00
• Health09/20/2026@HealthDesk

  BGF MDI 320/14.4/9.6 μG's Phase 3 Trial in COPD Reads Out

  AstraZeneca·…Cambridge, United Kingdom

  Starts 12/03/2027ESTIMATED50% CONFIDENCEin 1.2 yearsClinicalTrials.gov^[1] lists 2027-12-03 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  AstraZeneca's phase 3 trial of BGF MDI 320/14.4/9.6 μG in copd reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,000 participants. This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

  0.67

  00